查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1356860

戈谢氏症市场报告：2030 年趋势、预测与竞争分析

Gaucher Disease Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

戈谢氏症的趋势和预测

预计到 2030 年，全球戈谢氏症市场将达到 20 亿美元，2024 年至 2030 年年复合成长率为 2.1%。该市场的主要驱动因素是遗传异常、戈谢氏症及其相关症状的盛行率不断增加、消费者对诊断的认识不断提高以及治疗选择的便利可得性。全球戈谢病市场的未来前景广阔，医院、专科诊所和居家照护市场充满机会。

戈谢病市场洞察

Lucintel 预测，1 型预计在预测期内增长最快，因为它不影响中枢神经系统，而且是一种非神经系统疾病。

医院仍将是最大的细分市场。

由于医疗保健成本上升和大型企业的存在，预计亚太地区将在预测期内实现最高成长。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和业务风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些，由于材料或产品替代导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球戈谢氏症市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球戈谢氏症市场趋势（2018-2023）与预测（2024-2030）
  • 按疾病类型分類的全球戈谢氏症市场
    • 类型1
    • 2型
    • 类型3
    • 其他的
  • 按诊断分類的全球戈谢氏症市场
    • 体检
    • 验血
    • 影像检查
    • 怀孕前筛检和产前检测
    • 其他的
  • 按治疗分類的全球戈谢氏症市场
    • 外科手术
    • 药品
    • 其他的
  • 按最终用途分類的全球戈谢病市场
    • 医院
    • 专科诊所
    • 居家护理
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球戈谢氏症市场（按地区）
  • 北美戈谢病市场
  • 欧洲戈谢病市场
  • 亚太戈谢氏症市场
  • 其他区域戈谢氏症市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按疾病类型分類的全球戈谢氏症市场成长机会
    • 全球戈谢氏症市场诊断成长机会
    • 全球戈谢氏症治疗市场成长机会
    • 全球戈谢氏症市场成长机会（依最终用途）
    • 按地区分類的全球戈谢氏症市场成长机会
  • 全球戈谢氏症市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 全球戈谢病市场容量扩张
    • 全球戈谢病市场的合併、收购与合资企业
    • 认证和许可

第7章主要企业概况

  • ISU Abxis
  • Johnson & Johnson
  • Pfizer
  • Protalix Biotherapeutics
  • Sanofi SA
  • Takeda Pharmaceutical
简介目录

Gaucher Disease Trends and Forecast

The future of the global gaucher disease market looks promising with opportunities in the hospital, specialty clinic, and homecare markets. The global gaucher disease market is expected to reach an estimated $2.0 billion by 2030 with a CAGR of 2.1% from 2024 to 2030. The major drivers for this market are the increasing prevalence of genetic abnormalities, growing consumer awareness towards the gaucher disease and its relevant symptoms, diagnosis, and the easy availability of the treatment options.

A more than 150-page report is developed to help in your business decisions.

Gaucher Disease by Segment

The study includes a forecast for the global gaucher disease by disease type, diagnosis, treatment, end use, and region.

Gaucher Disease Market by Disease Type [Shipment Analysis by Value from 2018 to 2030]:

  • Type 1
  • Type 2
  • Type 3
  • Others

Gaucher Disease Market by Diagnosis [Shipment Analysis by Value from 2018 to 2030]:

  • Physical Exam
  • Blood Tests
  • Imaging Tests
  • Preconception Screening and Prenatal Testing
  • Others

Gaucher Disease Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Surgery
  • Medication
  • Others

Gaucher Disease Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Gaucher Disease Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Gaucher Disease Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies gaucher disease companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the gaucher disease companies profiled in this report include-

  • Isu Abxis
  • Johnson & Johnson
  • Pfizer
  • Protalix Biotherapeutics
  • Sanofi S.A.
  • Takeda Pharmaceutical

Gaucher Disease Market Insights

Lucintel forecasts that type 1 is expected to witness highest growth over the forecast period because it is condition does not affect the central nervous system "CNS" and becomes a non-neurological condition.

Hospitals will remain the largest segment.

APAC is expected to witness highest growth over the forecast period due to the increasing healthcare expenditure and presence of major players in this region.

Features of the Global Gaucher Disease Market

Market Size Estimates: Gaucher disease market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Gaucher disease market by various segments, such as by disease type, diagnosis, treatment, end use and region in terms of($B).

Regional Analysis: Gaucher disease market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different disease types, diagnosis, treatments, end uses, and region.s for the gaucher disease market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the gaucher disease market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the gaucher disease market size?

Answer: The global gaucher disease market is expected to reach an estimated $2.0 billion by 2030.

Q.2. What is the growth forecast for gaucher disease market?

Answer: The global gaucher disease market is expected to grow with a CAGR of 2.1% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the gaucher disease market?

Answer: The major drivers for this market are the increasing prevalence of genetic abnormalities, growing consumer awareness towards the gaucher disease and its relevant symptoms, diagnosis, and the easy availability of the treatment options.

Q.4. What are the major segments for gaucher disease market?

Answer: The future of the gaucher disease market looks promising with opportunities in the hospital, specialty clinic, and homecare markets.

Q.5. Who are the key gaucher disease market companies?

Answer: Some of the key gaucher disease companies are as follows:

  • ISU Abxis
  • Johnson & Johnson
  • Pfizer
  • Protalix Biotherapeutics
  • Sanofi S.A.
  • Takeda Pharmaceutical

Q.6. Which gaucher disease market segment will be the largest in future?

Answer: Lucintel forecasts that type 1 is expected to witness highest growth over the forecast period because it is condition does not affect the central nervous system "CNS" and becomes a non-neurological condition.

Q.7. In gaucher disease market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to the increasing healthcare expenditure and presence of major players in this region.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the gaucher disease market by disease type (type 1, type 2, type 3, and others), diagnosis (physical exam, blood tests, imaging tests, preconception screening and prenatal testing, and others), treatment (surgery, medication, and others), end use (hospitals, specialty clinics, homecare, and others), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Gaucher Disease Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Gaucher Disease Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Gaucher Disease Market by Disease Type
    • 3.3.1: Type 1
    • 3.3.2: Type 2
    • 3.3.3: Type 3
    • 3.3.4: Others
  • 3.4: Global Gaucher Disease Market by Diagnosis
    • 3.4.1: Physical Exam
    • 3.4.2: Blood Tests
    • 3.4.3: Imaging Tests
    • 3.4.4: Preconception Screening and Prenatal Testing
    • 3.4.5: Others
  • 3.5: Global Gaucher Disease Market by Treatment
    • 3.5.1: Surgery
    • 3.5.2: Medication
    • 3.5.3: Others
  • 3.6: Global Gaucher Disease Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Specialty Clinics
    • 3.6.3: Homecare
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Gaucher Disease Market by Region
  • 4.2: North American Gaucher Disease Market
    • 4.2.2: North American Gaucher Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.3: European Gaucher Disease Market
    • 4.3.1: European Gaucher Disease Market by Disease Type: Type 1, Type 2, Type 3, and Others
    • 4.3.2: European Gaucher Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.4: APAC Gaucher Disease Market
    • 4.4.1: APAC Gaucher Disease Market by by Disease Type: Type 1, Type 2, Type 3, and Others
    • 4.4.2: APAC Gaucher Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others
  • 4.5: ROW Gaucher Disease Market
    • 4.5.1: ROW Gaucher Disease Market by by Disease Type: Type 1, Type 2, Type 3, and Others
    • 4.5.2: ROW Gaucher Disease Market by End Use: Hospitals, Specialty Clinics, Homecare, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Gaucher Disease Market by Disease Type
    • 6.1.2: Growth Opportunities for the Global Gaucher Disease Market by Diagnosis
    • 6.1.3: Growth Opportunities for the Global Gaucher Disease Market by Treatment
    • 6.1.4: Growth Opportunities for the Global Gaucher Disease Market by End Use
    • 6.1.5: Growth Opportunities for the Global Gaucher Disease Market by Region
  • 6.2: Emerging Trends in the Global Gaucher Disease Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Gaucher Disease Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Gaucher Disease Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: ISU Abxis
  • 7.2: Johnson & Johnson
  • 7.3: Pfizer
  • 7.4: Protalix Biotherapeutics
  • 7.5: Sanofi S.A.
  • 7.6: Takeda Pharmaceutical